No Data
No Data
Fulcrum Therapeutics (NASDAQ:FULC) Readies Phase 3 Candidate With Blockbuster Potential
Fulcrum Therapeutics Initiated at Overweight by Cantor Fitzgerald
Fulcrum Therapeutics Initiated at Overweight by Cantor Fitzgerald
Fulcrum Therapeutics (FULC.US) was first covered by Cantor Fitzgerald, which gave it an increase rating, with a target price of $23.00.
Fulcrum Therapeutics (FULC.US) was first covered by Cantor Fitzgerald, which gave it an increase rating, with a target price of $23.00.
Cantor Fitzgerald Initiates Coverage On Fulcrum Therapeutics With Overweight Rating, Announces Price Target of $23
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight rating and announces Price Target of $23.
Buy Rating Reaffirmed for Fulcrum Therapeutics Amid Sanofi Partnership and Promising Drug Prospects
Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target Is $15
Fulcrum Therapeutics (FULC) has an average rating of outperform and price targets ranging from $5 to $19, according to analysts polled by Capital IQ. Price: 7.80, Change: +0.45, Percent Change: +6.12